Treatments based on LINGO-1 (LRR and Ig domain containing NOGO receptor interacting protein) antagonism and protein kinase B (Akt) activation in experimental models of cognitive loss in MS may assist to maintain memory function through the promotion of oligodendrocyte differentiation and myelination [145]. The gene discussed is AKT1; the disease is myeloid sarcoma.